Pipeline

Four R&D Programs based on BAPAI Platform:

First-in-class:
Resistant hypertension

Pivotal phase III study

(ongoing FDA approval)

Clinical Development of First-in-Class firibastat, the first drug candidate in the BAPAI class, for the treatment of high blood pressure

First-in-class:
Heart failure

Ongoing phase II study:

Quorum

Development of firibastat product for the treatment of heart failure

Best-in-class:
Optimized treatment of hypertension as monotherapy

Preclinical stage

(proof of concept on animals)

Optimization of BAPAI products and development of a “Best-in-Class” product

Hypertension in combination:
Firibastat + ACE

Preclinical stage

Development of therapeutic combinations involving a BAPAI with another antihypertensive drug

READ MORE
READ MORE
READ MORE
READ MORE